French Company Biosantech to Release Phase II Results on Its HIV Vaccine

Share Article

Biotsantech is developing a new therapeutic vaccine against AIDS currently in clinical phase IIa in France. The TAT OYI Vaccine candidate is a breakthrough innovation able to induce a cross-protective immunity and replication of several HIV subtypes.

There are 35 million people in the world with AIDS and many don't have access to current therapies.

What: News conference to announce results of Phase II study on a new therapeutic HIV vaccine

When: June 8th, 1:25 p.m. to 1:50 p.m.

Where: International Conference on Retroviruses and Novel Drugs--DoubleTree by Hilton Hotel Chicago - North Shore Conference Center9599 Skokie Boulevard, Skokie--Room 2B2

Who: Biotsantech is developing a new therapeutic vaccine against AIDS currently in clinical phase IIa in France. The TAT OYI Vaccine candidate is a breakthrough innovation able to induce a cross-protective immunity and replication of several HIV subtypes.

Dr Donatien Mavougou, who is in charge of the IMMUNOREX HIV program, will be a speaker at the conference prior to the news conference. The title of his presentation: “IMMUNOREXTM as vaccine approach by its ability to inhibit HIV-1 and co-infecting pathogens: the role of its lipid carrier. The news conference will be held after that presentation and Dr Mavoungou will talk about his collaboration with Biosantech.

Also attending the news conference from Biosantech are: CEO Mme Corinne Treger; Dr. Sonia Escaich; Virologist Dr. Jean de Mareuil; and Mr Michel Correa Director of the IIDSRSI Institute France.

Background:
Despite the success of antiretroviral tritherapy ART developed in the 1990s, there are still 35 million people living with HIV in the world and only 37 of those have access to current therapies. The development of an effective vaccine is hampered by the highly mutagenic nature of HIV. An effective therapeutic vaccine against several HIV subtypes could represent a major advance for a cost effective treatment of the HIV infection.

The HIV-Oyi variant was isolated in 1998 in monkeys. The virus strain called Oyi had a mutated TAT protein defective for transactivation. Several studies have shown that the presence of the Anti Tat immune response is correlated to long-term survival in humans.

Phase I results were completed in December 2014 and showed no adverse events or sign of toxicity.

About Biostantech
Biostantech is a private company founded by M. Roger Treger in 2011, and is based on the licensing of patientsand technology from CNRS. For more information, visit http://www.biosantech.org/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Martin
CMPR, Inc.
+1 (630) 670-2745
Email >
Visit website

Media